{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "DXCM",
  "name": "DexCom, Inc.",
  "url": "https://frontierpicks.com/dossiers/DXCM/",
  "json_url": "https://frontierpicks.com/dossiers/DXCM.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": "MEDIUM",
  "archetype": {
    "code": "a7",
    "n": 7
  },
  "current_thesis": "CGM leader's recovery has aged from catalyst-pop to an analyst-revision grind — Mizuho $90 (7/15), Truist $87 (7/16) into a ~7% two-day pop to $76.65 — but price is high-$70s still under the 200-EMA and the confirmed July 30 Q2 print is the binary; buying here chases extension into earnings risk.",
  "invalidation_trigger": "a daily close that breaches the risk threshold loses the recovery-base shelf and round number; secondarily, a Q2 miss or guide-down on the July 30 print, an Abbott Libre price/share headline, or the Medtech & diagnostics theme flipping to saturated would confirm the break.",
  "catalyst_date": null,
  "outcome": "INVALIDATED",
  "outcome_date": "2026-06-22",
  "invalidation_fired": true,
  "themes": [
    "medtech-diagnostics",
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Q3 2026 earnings date ~2026-10-29 is an aggregator estimate; Dexcom typically confirms the date about three weeks in advance.",
    "Consensus target differs by panel: $88.71 across 27 analysts (MarketBeat) vs $94.12 average (stockanalysis.com), both as of 2026-08-21.",
    "Recent insider sales run through pre-arranged Rule 10b5-1 plans (Foletta family trust plan adopted 2026-03-13), not discretionary decisions.",
    "DexCom has a history of outsized single-session post-earnings moves in both directions; gap risk around print dates is structural to the name.",
    "Levels cited use split/dividend-adjusted daily closes; unadjusted vendor quotes may show a different 52-week range."
  ],
  "body_markdown": "## Current Thesis\nThe binary this coverage flagged in July resolved on 2026-07-30, and the tape has spent the three weeks since converting that print into price. The last completed daily close, 2026-08-21, is $92.34 — the 52-week high itself, 0.0% below it, +28.1% over three months, RSI(14) 62.7. What has changed since the 2026-08-09 note is not the fundamental leg but who is left to raise. MarketBeat's target-change history shows the revision wave running 2026-07-31 through 2026-08-04 (Argus to $96 from $86, Buy, on 8/4) and then nothing dated through 2026-08-21 apart from a Weiss tier tweak to Hold on 8/11. Over that same stretch the shares added roughly 9% from the 8/7 close of $84.75. Price is now above the 27-analyst consensus target of $88.71 that MarketBeat carried on 2026-08-21; stockanalysis.com's panel showed an average of $94.12 the same day, so both panels place the tape at or through the street's own number. The narrative is **maturing** — the story is well understood, the operating data still supports it, but new sell-side flow has moderated and the 30-day calendar is empty. The narrative leg an investor is buying here is margin expansion at a CGM franchise that just took FY26 non-GAAP operating margin guidance to 23.5–24%, plus unpriced optionality in Type 2 non-insulin and the FDA TEMPO pilot. The cost of that leg is that the next hard company datapoint is roughly ten weeks out.\n\n## Bull Case\n- **Both guidance lines moved on 2026-07-30.** Q2 revenue $1.3084B versus $1.290B consensus, +13% reported and +12% organic; adjusted EPS $0.70 against $0.61 expected. FY26 revenue guidance to $5.180–5.250B, non-GAAP operating margin to 23.5–24% from 23–23.5%.\n- **Gross margin is measured, not forecast.** Q2 non-GAAP gross margin 64.1% versus 60.1% a year earlier, 400bp, attributed on the 7/30 call to manufacturing efficiency and normalized shipping. FY gross margin guidance ~64%.\n- **A new repurchase authorization sits behind the print.** Up to $1B running through 2027-06-30, disclosed alongside Q2, following $600M of stock retired during Q2 itself — a quarter that opened with the shares in the $60s–$70s.\n- **Regulatory positioning is dated and specific.** Dexcom was named the first participant in the FDA's TEMPO digital-health pilot on 2026-07-22, a program built with the CMS Innovation Center to generate real-world evidence on an AI glucose program spanning G7 and Stelo for prediabetes and Type 2 screening. Piper Sandler reiterated Overweight and $95 following that selection.\n- **Geography is carrying growth.** Q2 international revenue +19% reported and +16% organic against US +11%; G7 15 Day cleared Health Canada on 2026-07-13 (15.5-day wear, 8.0% MARD).\n- **The highest dated target is above the tape.** Argus $96 on 2026-08-04 remains the top confirmed print in the dated history, roughly 4% above the 8/21 close.\n\n## Bear Case\n- **Price has overtaken the consensus it was chasing.** $92.34 on 8/21 against a $88.71 27-analyst consensus target implies the street's average number sits below the tape; the reward argument now depends on a second round of raises that has not been filed since 8/4.\n- **The FY26 ceiling never moved.** Only the $5.160B floor lifted to $5.180B on 7/30; $5.250B has stood since the prior guide, and the range still brackets the $5.224B consensus figure. That is a de-risking rather than an acceleration.\n- **The multiple is doing work.** stockanalysis.com showed a $34.85B market cap, trailing P/E 36.41 and forward P/E 32.84 on 2026-08-21, against guided FY26 growth of 11–13%.\n- **An unverified target is circulating.** A syndicated analyst-wire item dated 2026-08-17 reported Citi moving to $105 from $88; MarketBeat's dated target history as of 2026-08-21 still shows Citi at $88 from 7/31. Until it appears in the change log it should be treated as unconfirmed, which matters because it is the only sell-side action anyone has cited between 8/4 and the high.\n- **Insider supply printed into the first leg.** A family trust tied to director Mark G.\n- **Momentum is thinner at the higher price.** RSI(14) read 65.1 at the 8/7 close of $84.75 in the prior note; it reads 62.7 at the 8/21 close of $92.34. The oscillator is lower at a materially higher price.\n\n## Setup & Price Structure\n- The 2026-08-21 close of $92.34 is the 52-week high, so there is no overhead supply from the past year and no reference point above.\n- The structure being defended is the breakout through the early-August high near $87.31 — the level the shares were 2.9% under at the 8/7 close of $84.75. Losing it on a daily close puts the tape back inside the pre-breakout range.\n- Crowding observables, stated as observables: distance from the 52-week high 0.0%; price ~4% above the 27-analyst consensus target of $88.71 as of 8/21; two dated 10b5-1 insider sales on 7/31 and 8/3; no earnings date inside 30 days; dated sell-side raises absent for 13 sessions while the shares gained roughly 9%.\n- What dates the maturing label: the revision cluster is 2026-07-31 to 2026-08-04, and the only entry after it in the dated history is a Weiss rating-tier change on 2026-08-11. Attention is not expanding; the position of price is.\n\n## Catalyst Calendar (next 30 days)\n- **2026-08-22 to 2026-09-21 — no company-confirmed event.** Price action inside this window is sector flow, index/fund rebalancing and residual revision follow-through rather than new company information.\n- **~2026-08-26 (est.) — conference-presentation release.** Dexcom has historically published an \"Announces Upcoming Conference Presentations\" release in late August (the 2025 edition was dated 2025-08-26). Not announced for 2026 as of 2026-08-21.\n- **~2026-09-09 (est.) — Wells Fargo Healthcare Conference, Boston (Sept 8–10).** Dexcom presented at the 2025 edition; 2026 participation is not confirmed. A fireside is the only realistic venue for an intra-quarter demand comment.\n- **~2026-09-15 (est.) — Morgan Stanley 24th Annual Global Healthcare Conference, New York (Sept 14–16).** Same conditional status.\n- **~2026-10-29 (est.) — Q3 2026 print.** Outside the window and the next hard binary. Aggregator estimate; Dexcom typically confirms about three weeks ahead.\n\n## What Would Change Our Mind\nThe structure carrying this is the breakout through the early-August high near $87.31, and the fundamental leg is a guidance ceiling that has not moved. A daily close below $87 surrenders that breakout and returns the shares to the range they spent the first week of August in; the same level failing on a weekly close would say the post-print re-rating has fully round-tripped its second leg.\n\nOn fundamentals, the Q3 report around 2026-10-29 leaving the $5.250B FY26 top untouched, or organic growth printing below the 12% Q2 rate, removes the argument that the floor-raise was the start of a series. A confirmed Abbott disclosure on Libre pricing or share, or a pump partner naming a non-Dexcom sensor, would attack the pricing narrative directly.\n\nThe view improves rather than breaks if a second firm files a dated target above Argus $96 — which would confirm the $105 wire item rather than leave it orphaned — or if a named national payer publishes a non-insulin Type 2 CGM coverage decision. Absent either, the 13-session gap in dated revisions is the sharpest evidence against paying up at the high.\n\n## Correlation Notes\n- Moves with the CGM and diabetes-device complex: Abbott (Libre) on the competitive side, Insulet and Tandem on the pump-integration side. A sensor-partner announcement at either pump name reprices Dexcom's attach-rate assumptions without Dexcom filing anything.\n- GLP-1 headlines from Lilly and Novo have historically been a shared shock to diabetes-device multiples; the 2023 drawdown in the group on obesity-drug news is the reference episode for how fast that correlation asserts itself.\n- High-multiple medtech with a forward P/E near 33 carries duration risk to the rate path alongside IHI/XLV beta, so a hawkish macro print can override company news in this window given the empty calendar.\n- Single-session post-earnings moves in this name have been outsized in both directions; the correlation to the sector breaks down entirely on print dates.",
  "first_seen": "2026-06-09",
  "last_analyzed": "2026-08-22T10:46:42+00:00",
  "last_synthesized": "2026-08-22",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}